Jazz Pharmaceuticals
JAZZ
553 hedge funds and large institutions have $7.45B invested in Jazz Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 100 funds opening new positions, 222 increasing their positions, 156 reducing their positions, and 53 closing their positions.
168% more call options, than puts
Call options by funds: $66.4M | Put options by funds: $24.7M
89% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 53
42% more repeat investments, than reductions
Existing positions increased: 222 | Existing positions reduced: 156
16% more capital inflows, than outflows
Capital inflows: $1.05B | Capital outflows: $902M
8% more funds holding
Funds holding: 511 → 553 (+42)
0.98% more ownership
Funds ownership: 97.81% → 98.79% (+0.98%)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$64.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$52.5M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$51.1M |
| 4 |
Perpetual Ltd
Sydney, New South Wales,
Australia
|
+$46.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$38.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$179M |
| 2 |
Camber Capital Management
Boston,
Massachusetts
|
-$142M |
| 3 |
Vestal Point Capital
New York
|
-$120M |
| 4 |
Millennium Management
New York
|
-$76.9M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$59.7M |
JAZZ Hedge Fund Activity: Q1 2025 in Review
553 of the 7,489 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2025, worth a combined $7.45B — up 2.3% from $7.28B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new JAZZ positions and 53 closed out — a net gain of 47 holders — while 222 added to existing stakes and 156 trimmed.
The largest buyer was Holocene Advisors, opening a new position worth an estimated $64.2M. The largest seller was Pacer Advisors, cutting an estimated $179M.
- 553 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2025, up from 511 in Q4 2024.
- Funds reported $7.45B of Jazz Pharmaceuticals stock for Q1 2025, up 2.3% quarter-over-quarter.
- 100 funds opened new Jazz Pharmaceuticals positions in Q1 2025 and 53 closed out, a net change of +47 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2025 was Holocene Advisors, an estimated $64.2M added.
- The largest Jazz Pharmaceuticals seller in Q1 2025 was Pacer Advisors, an estimated $179M sold.
Based on aggregated 13F filings for Q1 2025.